Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty

Al Ani Aysha, Clarissa Rentsch, Ralley Prentice, Doug Johnson, Robert V. Bryant, Mark G. Ward, Samuel P. Costello, Peter Lewindon, Simon Ghaly, Susan J. Connor, Jakob Begun, Britt Christensen

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.

Original languageEnglish
Pages (from-to)798-804
Number of pages7
JournalInternal Medicine Journal
Volume50
Issue number7
DOIs
Publication statusPublished - Jul 2020

Keywords

  • COVID-19
  • Crohn disease
  • immunosuppression
  • inflammatory bowel disease
  • SARS-CoV-2
  • ulcerative colitis

Cite this